Replies to post #646601 on NorthWest Biotherapeutics Inc (NWBO)

[antihama]

Jeannine Walston received DCVax-L to treat Grade III Anaplastic Astrocytoma in 2014. See this story

https://www.uclahealth.org/news/18-year-brain-tumor-survivor-thriving-from-3rd-awake-brain-surgery-immunotherapy-vaccine-from-dr-linda-liau-at-ucla

If you google her now, she seems to be doing great.

Steps to Success as a 25-Year Brain Tumor Survivor at Age 50 ... \ On March 18, 2023, Jeannine Walston became a 25-year brain tumor survivor; on October 6, 2023, ...

[ATLnsider]

I recommend that you get in touch with Dr. Liau and/or Dr. Prins at UCLA. The trial that included DCVax-L along with poly-ICLC was not just for brain tumor patients who were diagnosed with Glioblastoma.

It also included all malignant Grade III and Grade IV brain tumors. That includes Glioblastoma and some Astrocytomas.



https://assets.researchsquare.com/files/rs-3287211/v1/570baff706a2ae91b1cc7e7a.pdf

Also, you can take a look at the preprinted trial results for this trial. You will see that the patients who were diagnosed with a Grade III Astrocytoma had very good survival results when treated with DCVax-L along with poly-ICLC:

https://assets.researchsquare.com/files/rs-3287211/v1_covered_72e8e045-4db9-40aa-b629-f4a452ce8b55.pdf?c=1695835180

Also, it is my opinion that when DCVax-L is initially approved in the US, Canada, UK, Germany and the rest of the EU, the initial approved label will include all malignant Grade III and Grade IV gliomas, including Glioblastoma and Astrocytoma:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173058182

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173061962

[HappyLibrarian]

Welcome to NWBO investing.

From an investor standpoint now seems to be a good time and a good price to buy and you are likely to do better than investors who have waited far longer and none of us begrudge you that.

We are likely to have a mini-catalyst this month when NWBO announces submission to MHRA and this will likely help build excitement because the clock will be started on an up or down approval decision (which I believe will be up) as NWBO has home town advantage since the company manufactures in the UK and there is no effective treatment for GBM.

A lot of investors look for the chance to jump into stocks that will have a binary catalyst any day and that should attract new investors which will help raise the SP over time up until the catalyst when we will have the potential for the kind of increase we have waited a decade for.

From a patient family member perspective the outlook is not nearly as positive. DCVax-L and Direct are great products and you should investigate then first and see if they are available via compassionate use or a trial for those close to you. Unfortunately at the rate things have been going, neither of these products is likely to be available with insurance reimbursement within a time frame for someone already diagnosed with cancer like your family member. Thus while NWBO is likely a rewarding investment you would do well to continue due diligence on the overall treatment landscape since time is probably if the essence for your relative.